Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
696
¥ million (year-on-year decrease in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings report2026年3月期 第2四半期5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥35,253 million+8.9%
Operating profit¥2,649 million-20.8%
Ordinary income¥2,660 million-19.7%
Net income¥2,226 million -13.0%interim net income attributable to owners of the parent
Selling, general and administrative expenses¥143 hundred million
Full-year earnings forecast
Net Sales
¥71,000 million
Operating profit
¥6,000 million
Ordinary income
¥6,000 million
Profit attributable to owners of the parent
¥5,000 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
物価上昇の継続、米国の通商政策の動向、ウクライナや中東情勢の長期化等による先行き不透明感、医療用医薬品事業・動物用医薬品事業の堅調推移、海外事業の売上寄与、研究開発費等の増加
New initiatives
- 将来の成長に向けたパイプライン拡充・創薬力強化を目的とした研究開発投資の積極推進
- AKP-022、LPRI-CF113、AKP-SMD106、MCN-009等の研究開発継続・準備
Key KPIsA metric the company considers important as a management benchmark.
- Ratio of sales from branded products43.2 %Year on year against the same period last year+1.8 percentage points
- Share of sales from generic drugs56.8 %
- 産婦人科領域売上高比率46.5 %
- 内科（消化器・甲状腺）領域売上高比率30.7 %
- 泌尿器科領域売上高比率6.2 %
- その他内科等領域売上高比率16.6 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
主要製品について薬価と数量の増減要因を記載（例：チラーヂンは薬価アップの影響を消化し数量も増加、ドロエチは薬価ダウンだが想定以上に数量増）Segment results
- Prescription Pharmaceutical BusinessNet Sales¥29,255 millionYear on year against the same period last year+2.2%
- Animal Health BusinessNet Sales¥3,765 millionYear on year against the same period last year+3.4%
- Overseas BusinessNet Sales¥2,133 millionYear on year against the same period last yearNo comparable period
- Other businessesNet Sales¥99 millionYear on year against the same period last year-11.8%
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | 2026年3月期 第2四半期 |
| Net Sales | ¥35,253 million (YoY +8.9%) |
| Operating profit | ¥2,649 million (YoY -20.8%) |
| Ordinary income | ¥2,660 million (YoY -19.7%) |
| Net income | ¥2,226 million (interim net income attributable to owners of the parent) (YoY -13.0%) |
| Selling, general and administrative expenses | ¥143 hundred million |
| Full-year earnings forecast | Net Sales ¥71,000 million / Operating profit ¥6,000 million / Ordinary income ¥6,000 million / Profit attributable to owners of the parent ¥5,000 million |
| Segment results | Segment Prescription Pharmaceutical Business / Net Sales ¥29,255 million / Year on year against the same period last year 2.2, Segment Animal Health Business / Net Sales ¥3,765 million / Year on year against the same period last year 3.4, Segment Overseas Business / Net Sales ¥2,133 million / Year on year against the same period last year No comparable period, Segment Other businesses / Net Sales ¥99 million / Year on year against the same period last year -11.8 |
| Breakdown of Factors Affecting the Change | 物価上昇の継続、米国の通商政策の動向、ウクライナや中東情勢の長期化等による先行き不透明感、医療用医薬品事業・動物用医薬品事業の堅調推移、海外事業の売上寄与、研究開発費等の増加 |
| Key KPIs | Indicator name Ratio of sales from branded products / Value 43.2 % / Year on year against the same period last year +1.8 percentage points, Indicator name Share of sales from generic drugs / Value 56.8 % / Year on year against the same period last year Not disclosed, Indicator name 産婦人科領域売上高比率 / Value 46.5 % / Year on year against the same period last year Not disclosed, Indicator name 内科（消化器・甲状腺）領域売上高比率 / Value 30.7 % / Year on year against the same period last year Not disclosed, Indicator name 泌尿器科領域売上高比率 / Value 6.2 % / Year on year against the same period last year Not disclosed, Indicator name その他内科等領域売上高比率 / Value 16.6 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | 主要製品について薬価と数量の増減要因を記載（例：チラーヂンは薬価アップの影響を消化し数量も増加、ドロエチは薬価ダウンだが想定以上に数量増） |
| New initiatives | 将来の成長に向けたパイプライン拡充・創薬力強化を目的とした研究開発投資の積極推進, AKP-022、LPRI-CF113、AKP-SMD106、MCN-009等の研究開発継続・準備 |
Items this document does not state (18)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、医療用医薬品事業や動物用医薬品事業が堅調に推移したことに加え、海外事業の売上寄与により増加した。利益面では研究開発費等が増加したため減益となった。通期予想の修正は、Hataphar社の輸入品販売取引の売上計上を総額から純額へ変更したことと、将来の成長に向けた研究開発投資の積極的な推進により研究開発費等が増加する見込みとなったことによる。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.